BACKGROUND: Satraplatin is an oral platinum compound that has demonstrated efficacy and tolerability in prostate cancer.
Preclinical synergy between bevacizumab and platinum has been noted.
METHODS: Docetaxel-pretreated metastatic castrate-resistant prostate cancer patients with disease progression were eligible. Satraplatin 80mg/m2 orally on days 1 to 5, prednisone 5mg twice daily, and bevacizumab 10mg/kg on day 1, and 15mg/kg on day 15 were administered in 35-day cycles.
RESULTS: Thirty one patients were enrolled. Grade 3 or 4 toxicities were pulmonary embolism in 2 patients and thrombocytopenia in 1 patient. 31% of the patients had a≥30% decline in prostate-specific antigen. Median time to progression was 7.0 months (90% confidence interval [CI] 4.7-8.5mo) and median overall survival was 11.2 months (90% CI 9.1-16.4mo). Polymorphism in the excision repair cross-complementation-1 (ERCC-1) gene was associated with time to progression (hazard ratio = 1.91). A circulating tumor cell count≥5was moderately prognostic of overall survival (hazard ratio = 1.49) as compared with CTC < 5.
CONCLUSIONS: The combination was tolerable, and revealed promising efficacy in metastatic castrate-resistant prostate cancer. ERCC1 genotype maybe predictive of clinical benefit with platinum-based therapy in metastatic prostate cancer.
Written by:
Vaishampayan UN, Fontana J, Heilbrun LK, Smith D, Heath E, Dickow B, Figg WD. Are you the author?
Department of Oncology, Department of Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Reference: Urol Oncol. 2013 Feb 20. pii: S1078-1439(12)00423-1.
doi: 10.1016/j.urolonc.2012.11.017
PubMed Abstract
PMID: 23433892
